Celtic Therapeutics Holdings L.P., Resolvyx deal

Resolvyx granted Celtic an exclusive option to license exclusive, worldwide rights to RX-10045 for all ophthalmic indications. The topical synthetic analog of resolvin E1 (RvE1) is expected to start...